Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

FASEB Journal

Volumn 22, Issue 7, 2008, Pages 2214-2222

  Akhmetshina, Alfiya ^a   Dees, Clara ^a   Pileckyte, Margarita ^b   Maurer, Britta ^c   Axmann, Roland ^a   Jüngel, Astrid ^c   Zwerina, Jochen ^a   Gay, Steffen ^c   Schett, Georg ^a   Distler, Oliver ^c   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Fibroblasts; Scleroderma; Systemic sclerosis; TGF ; Translational

Indexed keywords

ABELSON KINASE; BLEOMYCIN; DASATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCLEROPROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENCY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ADULT; AGE OF ONSET; AGED; BIOPSY; CELLS, CULTURED; FIBROBLASTS; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; THIAZOLES;

EID: 46749154199     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-105627     Document Type: Article

References (29)

1. Scheja, A., Hellmer, G., Wollheim, F. A., and Akesson, A. (1993) Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Br. J. Rheumatol. 32, 59-62
2. Hesselstrand, R., Scheja, A., and Akesson, A. (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann. Rheum. Dis. 57, 682-686
3. Varga, J., and Abraham, D. (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557-567
4. Czochra, P., Klopcic, B., Meyer, E., Herkel, J., Garcia-Lazaro, J. F., Thieringer, F., Schirmacher, P., Biesterfeld, S., Galle, P. R., Lohse, A. W., and Kanzler, S. (2006) Liver fibrosis induced by hepatic overexpression of PDGF-β in transgenic mice. J. Hepatol. 45, 419-428
5. Santiago, B., Gutierrez-Canas, I., Dotor, J., Palao, G., Lasarte, J. J., Ruiz, J., Prieto, J., Borras-Cuesta, F., and Pablos, J. L. (2005) Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125, 450-455
6. Sonnylal, S., Denton, C. P., Zheng, B., Keene, D. R., He, R., Adams, H. P., Vanpelt, C. S., Geng, Y. J., Deng, J. M., Behringer, R. R., and de Crombrugghe, B. (2007) Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 56, 334-344
7. Distler, J. H., Jungel, A., Huber, L. C., Schulze-Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., and Distler, O. (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56, 311-322
8. Daniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J., Murphy, S. J., Limper, A. H., and Leof, E. B. (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114, 1308-1316
9. Wang, S., Wilkes, M. C., Leof, E. B., and Hirschberg, R. (2005) Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J. 19, 1-11
10. Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., and Fukui, H. (2005) Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. 288, G907-G913
11. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037
12. Atallah, E., Kantarjian, H., and Cortes, J. (2007) Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin. Lymphoma Myeloma 7, S105-S112
13. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J. D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L., and Ottmann, O. G. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551
14. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M. A., Iyer, V., Chen, T. T., Huang, F., Decillis, A. P., and Sawyers, C. L. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541
15. Kantarjian, H., Jabbour, E., Grimley, J., and Kirkpatrick, P. (2006) Dasatinib. Nat. Rev. Drug Discov. 5, 717-718
16. Skhirtladze, C., Distler, O., Dees, C., Akhmetshina, A., Busch, N., Venalis, P., Zwerina, J., Spriewald, B., Pileckyte, M., Schett, G., and Distler, J. H. (2008) Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. In press
17. LeRoy, E. C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T. A., Jr., Rowell, N., and Wollheim, F. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202-205
18. Distler, J. H., Jungel, A., Huber, L. C., Seemayer, C. A., Reich, C. F., 3rd, Gay, R. E., Michel, B. A., Fontana, A., Gay, S., Pisetsky, D. S., and Distler, O. (2005) The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc. Natl. Acad. Sci. U. S. A. 102, 2892-2897
19. Distler, J. H., Jungel, A., Caretto, D., Schulze-Horsel, U., Kowal-Bielecka, O., Gay, R. E., Michel, B. A., Muller-Ladner, U., Kalden, J. R., Gay, S., and Distler, O. (2006) Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 54, 214-225
20. Kamath, A. V., Wang, J., Lee, F. Y., and Marathe, P. H. (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 61, 365-376
21. Kaur, P., Feldhahn, N., Zhang, B., Trageser, D., Muschen, M., Pertz, V., Groffen, J., and Heisterkamp, N. (2007) Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol. Cancer 6, 67
22. Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., Wen, M. L., Kramer, R., Blackwood-Chirchir, A., and Lee, F. Y. (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin. Cancer Res. 12, 7180-7186
23. Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S., Lee, F. Y., Donato, N. J., Abbruzzese, J. L., Baker, C. H., and Gallick, G. E. (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168, 962-972
24. Abdollahi, A., Li, M., Ping, G., Plathow, C., Domhan, S., Kiessling, F., Lee, L. B., McMahon, G., Grone, H. J., Lipson, K. E., and Huber, P. E. (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925-935
25. Dorey, K., Engen, J. R., Kretzschmar, J., Wilm, M., Neubauer, G., Schindler, T., and Superti-Furga, G. (2001) Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 20, 8075-8084
26. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., and Pendergast, A. M. (1999) c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13, 2400-2411
27. O'Hare, T., Walters, D. K., Stoffregen, E. P., Sherbenou, D. W., Heinrich, M. C., Deininger, M. W., and Druker, B. J. (2005) Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 11, 6987-6993
28. Beham-Schmid, C., Apfelbeck, U., Sill, H., Tsybrovsky, O., Hofler, G., Haas, O. A., and Linkesch, W. (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99, 381-383
29. Bueso-Ramos, C. E., Cortes, J., Talpaz, M., O'Brien, S., Giles, F., Rios, M. B., Medeiros, L. J., and Kantarjian, H. (2004) Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 101, 332-336